Born: March, 1970
Education
October 1993 - December 1996: M.D., Hadassah Medical School, Hebrew University, Jerusalem.
October 1990 - December 1993: B.Sc. in Medical Sciences, Hadassah Medical School, Hebrew University, Jerusalem.
Internship
June 1997 - May 1998: Rotating internship Hadassah University Hospital.
Residencies
Oncology
June 2004-May 2008: Oncology Department at Hadassah University Hospital (Ein-Kerem).
Internal Medicine
January 2002 – June 2004: Internal Medicine Department at Shaare Zedek Medical Center.
May 2001 – November 2001: Nuclear Medicine Department at Hadassah University Hospital (Ein-Kerem).
November 1999 – December 2000: Internal Medicine Department at Hadassah University Hospital (Mt. Scopus).
Licensure and certificates
* June 2008: Israeli board certified in Oncology (License number 1-26625)
* April 2007: Phase II exam, Oncology and Radiotherapy
* June 2006: Phase I exam, Oncology and Radiotherapy
* August 2004: Israeli board certified in Internal Medicine (License number 21108)
* November 2003: Phase II exam, Internal Medicine (Cum Laude)
* June 2002: Phase I exam, Internal Medicine
* September 1998: The USA Education Commission for Foreign Medical Graduate Certification (ECFMG).
* May 1998: License to practice medicine (license number 30420)
Academic Appointments:
October 2004: Instructor in oncology, Hebrew University Hadassah Medical School
Student Guidance of research project as part of the Medical School graduation requirements:
Nadav Michaan- Comparative study of histo-pathological characteristics of breast cancer in women who underwent in vitro fertilization and age matched controls
Betty Abitbul- The correlation of biomarkers in primary breast tumor and the involved lymph nodes and relevance to the clinical outcome.
Academic Research Experience
* September 2009- August 2010: Postdoctoral Research fellowship Exeperimental Pediatrics Department, M. D. Anderson Houston, TX, under the direction of Dennis Hughes, M.D, PhD.
* September 2008- August 2009: Postdoctoral fellowship Sarcoma Research Center Department of Surgical Oncology, M. D. Anderson Houston, TX, under the direction of Dina Chelouche Lev, M.D.
* October 1998 – September 1999: Associate researcher in the Department of Biochemistry and Molecular Biology, University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, under Robert A. Steinberg, PhD.
(The project was admitted for basic science research by The Israeli Medical Scientific Council as part of the residency requirements).
Grants and awards
* The Stanford and Joan Alexander Foundation-Recipient of a fellowship grant 100,000$/per year September 2008-August 2011
Sarcoma Research
* The American Physicians Fellowship for Medicine in Israel (APF)- Recipient of fellowship grant 10,000$ September 2008-August 2009
Sarcoma research
* Israel Cancer Association 14,500 NIS September 2008-August 2010
Sarcoma research
* Israel Cancer Association 90,000 NIS 2006-2007- Co-investigator
Testing the correlation of biomarker expression between primary tumor and lymph-node metastases; a new prognostic factor influencing treatment decisions for node-positive breast cancer patients?
* Young clinician funding 20,000 NIS/Y 2005-2006- Principal investigator
Testing the correlation of biomarker expression between primary tumor and lymph-node metastases; is it a new predictive factor influencing treatment decisions for node-positive breast cancer patients?
* Woman's health grant 70,000 NIS/Y 2005-2006- Principal investigator
Testing the correlation of biomarker expression between primary tumor and lymph-node metastases; a new prognostic factor influencing treatment decisions for node-positive breast cancer patients?
* Dean's teaching award – Faculty of Medicine Hebrew University 2006
* Faculty prize for excellence in clinical practice- Hadassah Hebrew-University Medical Center 2006
Publications
Reviewed manuscripts:
1. Katz D., Boonsirikamchai P., Choi H., Lazar A.J., Wang w.L, Xiao L, Benjamin R.S., Araujo D.M.. Efficacy of first-line doxorubicin and ifosfamide in myxoid liposarcoma (Submitted to Cancer September 2010).
2. Katz D., Mazeh,H, Divinsky L, Temper M, Ospovat, I, Salah A,Galinsky D, Uziely B, Peretz T. Fertility following chemotherapy for breast cancer in women 38 yrs and younger: the proof is in the pregnancy. (in progress).
3. Katz D., Lazar A.J., Lev D. Targeting malignant peripheral nerve sheet tumors (MPNST); molecular insights into signaling pathways and their clinical implications. Expert Review in Molecular Medicine 2009 Oct 19;11:e30
4. Katz D, Paltiel O, Peretz T, Revel A, Sharon N, Maly B, Michan N, Sklair-Levy M, Allweis T. Beginning IVF Treatments after age 30 increases the risk of breast cancer: Results of a case-control study. Breast Journal 14(6):517-522, November/December 2008.
5. Katz D, Peretz T, Ospovat I, Salim N, Ramu N, Hovav N, Uziely B. Expect the unexpected: Peritoneal spread- late relapse presentation of breast cancer. IMAJ 10:310–311, April 2008.
6. Meirow D, Katz D, Rabinovici Y, Or R, Shufaro Y, Ben-Yehuda D. Prevention of severe menorrhagia in oncology patients with treatment-induced thrombocytopenia: by luteizing releasing hormone agonist and depo medroxyprogesterone acetate. Cancer 107:1634-1641, October 2006.
7. Katz D., Segal A., Alberton J., Jurim O., Reissman P., Catane R., Cherny N. Neoadjuvant imatinib as therapy for unresectable gastrointestinal stromal tumor. Anti-Cancer Drugs. 15(6):599-602, July 2004.
8. Katz D., Aharoni D. Lytic Lesions in Breast Cancer. N Engl J Med. 351(27):2850, Decmber 2004.
Abstracts
1. Dumont A.G., Trent J.C., Yang Y., Katz D., Dumont S.N., Reynoso D.G., Hughes D.P. Histone deacetylase inhibitor SAHA upregulates Notch signaling resulting by a growth arrest in Gastrointestinal Stromal Tumor cells. Poster presentation at the 16th Annual CTOS Meeting; November 11-13, 2010 Paris, France.
2. Wang W.L, Katz D., Araujo D.M., Ravi V., Ludwig J.A., Trent J., Patel S.R., Lewis V.O., Lin P., Pollock R.E., Guadagnolo A., Zagars G., Benjamin R.S., Madewell J.E., Lazar A.J. Extensive fatty maturation can be seen in myxoid liposarcomas treated with neoadjuvant doxorubicin and ifosfamide and preoperative radiation therapy. Poster presentation at the 16th Annual CTOS Meeting; November 11-13, 2010 Paris, France.
3. Goldberg H., Stern M., Risel S., Kuten A., Evron E., Peretz T., Katz D Co−Administration of GnRH−Agonists with Adjuvant Chemotherapy in Young Breast Cancer Patients: The Effect on Ovarian Function and on Clinical Outcome.. Poster presentation at the 33rd Annual San Antonio Breast Cancer Symposium, December 8 - 12, 2010 in San Antonio, Texas
4. Katz D, Hamburger D, Divinsky L, Temper M, Ospovat O, Salah A, Galinsky D, Peretz T. Fertility and pregnancy in patients below the age of 35 following chemotherapy for breast cancer. The 31st Annual San Antonio Breast Cancer Symposium 2008 poster presentation. Abstract 6148.
5. Berenstein T, Katz D, Applbaum Y, Peyser A. Efficacy of percutaneous radiofrequency ablation for the treatment of chondroblastoma and chondromyxoid-fibroma - preliminary results. The 28th Annual Meeting of the Israel Orthopedic Association 2008 oral presentation.
6. Katz D., Paltiel O., Ravel A., Sharon N., Slair-Levy M., Mishan N., Peretz T., Allweis T.M. A comparison of treatment characteristics in women undergoing in vitro fertilization who did and did not develop breast cancer. Fifth annual meeting of the Israeli Society for oncology and radiation therapy, Eilat 2006 oral presentation-Best abstract award.
7. Katz D., Maly B., Allweis TM., Peretz T. Different expression of estrogen & progesterone receptors (ER/PR) in primary breast tumor (PBT) and involved axillary nodes (IAN). Fourth annual meeting of the Israeli Society for oncology and radiation therapy, Eilat 2005 poster presentation.
8. Katz D., Segal A., Alberton J., Jurim O., Reissman P., Catane R., Cherny N. Neoadjuvant imatinib as therapy for unresectable gastrointestinal stromal tumor. Third annual meeting of the Israeli Society for oncology and radiation therapy, Dead Sea 2004. Best poster award.
9. Katz D., Chajek-Shaul T., Ben-Neriah Z., Dresner Pollak R., Diabetes mellitus, proteinuria, gonadal dysgenesis and genital malforamations in two Muslim Arab sisters – a new variant of MODY? Israel Endocrine Society Annual Meeting, Tel-Aviv, p. A-17, 2001.